MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
MacroGenics (NASDAQ:MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. President & CEO Eric Risser will deliver a presentation on Monday, September 8, 2025, at 11:30am ET in New York.
Investors can access the presentation webcast through the company's investor relations website, with a replay available for 30 days following the event.
MacroGenics (NASDAQ:MGNX), azienda biofarmaceutica specializzata in terapie antitumorali basate su anticorpi, ha annunciato la sua partecipazione alla 27ª Conferenza Globale Annuale sugli Investimenti di H.C. Wainwright. Il Presidente e CEO Eric Risser terrà una presentazione il lunedì 8 settembre 2025 alle 11:30 ET a New York.
Gli investitori potranno seguire la presentazione in webcast tramite il sito per gli investitori della società; la registrazione sarà disponibile in replica per 30 giorni dopo l'evento.
MacroGenics (NASDAQ:MGNX), compañía biofarmacéutica especializada en terapias contra el cáncer basadas en anticuerpos, ha anunciado su participación en la 27.ª Conferencia Anual Global de Inversiones de H.C. Wainwright. El presidente y CEO Eric Risser ofrecerá una presentación el lunes 8 de septiembre de 2025 a las 11:30 ET en Nueva York.
Los inversores podrán acceder a la transmisión en directo a través del sitio web de relaciones con inversores de la compañía; la reproducción estará disponible durante 30 días tras el evento.
MacroGenics (NASDAQ:MGNX), 항체 기반 항암 치료제를 개발하는 바이오제약회사로서 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 사장 겸 CEO Eric Risser은 2025년 9월 8일 월요일 동부시각 오전 11:30에 뉴욕에서 발표를 진행합니다.
투자자들은 회사의 투자자 관계 웹사이트를 통해 발표 웹캐스트에 접속할 수 있으며, 이벤트 종료 후 30일간 재생(리플레이)이 제공됩니다.
MacroGenics (NASDAQ:MGNX), société biopharmaceutique spécialisée dans les traitements anticancéreux à base d'anticorps, a annoncé sa participation à la 27e conférence annuelle mondiale sur l'investissement organisée par H.C. Wainwright. Le président-directeur général Eric Risser présentera le lundi 8 septembre 2025 à 11h30 ET à New York.
Les investisseurs pourront suivre la présentation en webcast via le site relations investisseurs de la société ; le replay sera disponible pendant 30 jours après l'événement.
MacroGenics (NASDAQ:MGNX), ein biopharmazeutisches Unternehmen, das sich auf antikörperbasierte Krebsbehandlungen spezialisiert hat, kündigte seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference an. Präsident und CEO Eric Risser wird am Montag, den 8. September 2025, um 11:30 Uhr ET in New York eine Präsentation halten.
Investoren können die Präsentation über die Investor-Relations-Website des Unternehmens per Webcast verfolgen; eine Aufzeichnung steht für 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com
FAQ
When is MacroGenics (MGNX) presenting at the H.C. Wainwright Conference?
Who will be presenting for MacroGenics at the H.C. Wainwright Conference?
How can investors access MacroGenics' H.C. Wainwright Conference presentation?
What is MacroGenics' (MGNX) main business focus?
